EMA Authorised: Harvoni (ledipasvir;sofosbuvir) — Gilead Sciences Ireland UC

View source ↗

Summary

The EMA authorised Harvoni (ledipasvir and sofosbuvir) for chronic hepatitis C, with decision dated 12 January 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• HARVONI (Ledipasvir and Sofosbuvir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic. MAH: Gilead Sciences Ireland UC. Decision date: 12/01/2023. Accelerated assessment